Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels

Circulation Research

Volumn 116, Issue 1, 2015, Pages 127-137

  Ballou, Lisa M ^a   Lin, Richard Z ^a,b   Cohen, Ira S ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cav1.2 calcium channel; Kv11.1 voltage gated channel, human; Kv7.1 potassium channel; long QT syndrome; Nav1.5 voltage gated sodium channel

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; CALCIUM CHANNEL L TYPE; DACTOLISIB; DASATINIB; DOFETILIDE; ION CHANNEL; ISOPRENALINE; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM CHANNEL; PROTEIN KINASE B; SODIUM CHANNEL; TERFENADINE;

CALCIUM CURRENT; DEPHOSPHORYLATION; DIABETES MELLITUS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; SODIUM CURRENT; ACTION POTENTIAL; ANIMAL; HEART MUSCLE CONDUCTION SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACTION POTENTIALS; ANIMALS; HEART CONDUCTION SYSTEM; HUMANS; ION CHANNELS; LONG QT SYNDROME; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 84920830370     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.303975     Document Type: Review

References (98)

1. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:329-341. doi: 10.1038/nrm2882.
2. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem. 2001;70:535-602. doi: 10.1146/annurev.biochem.70.1.535.
3. Lu Z, Jiang YP, Wang W, Xu XH, Mathias RT, Entcheva E, Ballou LM, Cohen IS, Lin RZ. Loss of cardiac phosphoinositide 3-kinase p110 alpha results in contractile dysfunction. Circulation. 2009;120:318-325. doi: 10.1161/CIRCULATIONAHA.109.873380.
4. Sun H, Kerfant BG, Zhao D, Trivieri MG, Oudit GY, Penninger JM, Backx PH. Insulin-like growth factor-1 and PTEN deletion enhance cardiac L-type Ca2+ currents via increased PI3Kalpha/PKB signaling. Circ Res. 2006;98:1390-1397. doi: 10.1161/01.RES.0000223321.34482.8c.
5. Ban K, Cooper AJ, Samuel S, Bhatti A, Patel M, Izumo S, Penninger JM, Backx PH, Oudit GY, Tsushima RG. Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosinemediated preconditioning. Circ Res. 2008;103:643-653. doi: 10.1161/CIRCRESAHA.108.175018.
6. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D, Stoyanova S, Vanhaesebroeck B, Dhand R, Nürnberg B. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science. 1995;269:690-693.
7. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJ, Okkenhaug K, Vanhaesebroeck B. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A. 2008;105:8292-8297. doi: 10.1073/pnas.0707761105.
8. Kurosu H, Maehama T, Okada T, Yamamoto T, Hoshino S, Fukui Y, Ui M, Hazeki O, Katada T. Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110beta is synergistically activated by the betagamma subunits of G proteins and phosphotyrosyl peptide. J Biol Chem. 1997;272:24252-24256.
9. Ballou LM, Chattopadhyay M, Li Y, Scarlata S, Lin RZ. Galphaq binds to p110alpha/p85alpha phosphoinositide 3-kinase and displaces Ras. Biochem J. 2006;394:557-562. doi: 10.1042/BJ20051493.
10. Lu Z, Jiang YP, Ballou LM, Cohen IS, Lin RZ. Galpha q inhibits cardiac L-type Ca2+ channels through phosphatidylinositol 3-kinase. J Biol Chem. 2005;280:40347-40354. doi: 10.1074/jbc.M508441200.
11. Patrucco E, Notte A, Barberis L, et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell. 2004;118:375-387. doi: 10.1016/j. cell.2004.07.017.
12. Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association with the ribosome. Cell. 2011;144:757-768. doi: 10.1016/j. cell.2011.02.014.
13. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol. 2010;11:9-22. doi: 10.1038/nrm2822.
14. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell. 2001;104:569-580.
15. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999;97:175-187.
16. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795-803.
17. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet. 1997;17:338-340. doi: 10.1038/ng1197-338.
18. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996;12:17-23. doi: 10.1038/ng0196-17.
19. Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995;376:683-685. doi: 10.1038/376683a0.
20. Medeiros-Domingo A, Kaku T, Tester DJ, Iturralde-Torres P, Itty A, Ye B, Valdivia C, Ueda K, Canizales-Quinteros S, Tusié-Luna MT, Makielski JC, Ackerman MJ. SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation. 2007;116:134-142. doi: 10.1161/CIRCULATIONAHA.106.659086.
21. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, Napolitano C, Schwartz PJ, Joseph RM, Condouris K, Tager-Flusberg H, Priori SG, Sanguinetti MC, Keating MT. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004;119:19-31. doi: 10.1016/j.cell.2004.09.011.
22. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805-811.
23. Hedley PL, Jørgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, Corfield VA, Christiansen M. The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat. 2009;30:1486-1511. doi: 10.1002/humu.21106.
24. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022. doi: 10.1056/NEJMra032426.
25. Okin PM, Devereux RB, Lee ET, Galloway JM, Howard BV; Strong Heart Study. Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. Diabetes. 2004;53:434-440.
26. Rossing P, Breum L, Major-Pedersen A, Sato A, Winding H, Pietersen A, Kastrup J, Parving HH. Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus. Diabet Med. 2001;18:199-205.
27. Veglio M, Borra M, Stevens LK, Fuller JH, Perin PC. The relation between QTc interval prolongation and diabetic complications. The EURODIAB IDDM Complication Study Group. Diabetologia. 1999;42:68-75.
28. Dennis A, Wang L, Wan X, Ficker E. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans. 2007;35:1060-1063. doi: 10.1042/BST0351060.
29. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, Wible BA, Brown AM. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol. 2004;66:33-44. doi: 10.1124/mol.66.1.33.
30. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, Reynolds W, Rampe D. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther. 2005;312:316-323. doi: 10.1124/jpet.104.073692.
31. Mitcheson JS. hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem Res Toxicol. 2008;21:1005-1010. doi: 10.1021/tx800035b.
32. Mitcheson JS, Chen J, Sanguinetti MC. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol. 2000;115:229-240.
33. Lu Z, Wu CY, Jiang YP, Ballou LM, Clausen C, Cohen IS, Lin RZ. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med. 2012;4:131ra50. doi: 10.1126/scitranslmed.3003623.
34. Kerfant BG, Gidrewicz D, Sun H, Oudit GY, Penninger JM, Backx PH. Cardiac sarcoplasmic reticulum calcium release and load are enhanced by subcellular cAMP elevations in PI3Kgamma-deficient mice. Circ Res. 2005;96:1079-1086. doi: 10.1161/01.RES.0000168066.06333.df.
35. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10:143-153. doi: 10.1038/nrclinonc.2013.10.
36. Roy M, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation. 1996;94:817-823.
37. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 1993;269:1532-1536.
38. Yang T, Chun YW, Stroud DM, Mosley JD, Knollmann BC, Hong C, Roden DM. Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation. 2014;130:224-234. doi: 10.1161/CIRCULATIONAHA.113.007765.
39. Magyar J, Rusznák Z, Szentesi P, Szûcs G, Kovács L. Action potentials and potassium currents in rat ventricular muscle during experimental diabetes. J Mol Cell Cardiol. 1992;24:841-853.
40. Shimoni Y. Inhibition of the formation or action of angiotensin II reverses attenuated K+ currents in type 1 and type 2 diabetes. J Physiol. 2001;537:83-92.
41. Lengyel C, Virág L, Bíró T, Jost N, Magyar J, Biliczki P, Kocsis E, Skoumal R, Nánási PP, Tóth M, Kecskeméti V, Papp JG, Varró A. Diabetes mellitus attenuates the repolarization reserve in mammalian heart. Cardiovasc Res. 2007;73:512-520. doi: 10.1016/j.cardiores.2006.11.010.
42. Zhang Y, Xiao J, Lin H, Luo X, Wang H, Bai Y, Wang J, Zhang H, Yang B, Wang Z. Ionic mechanisms underlying abnormal QT prolongation and the associated arrhythmias in diabetic rabbits: a role of rapid delayed rectifier K+ current. Cell Physiol Biochem. 2007;19:225-238. doi: 10.1159/000100642.
43. Shimoni Y, Chuang M, Abel ED, Severson DL. Gender-dependent attenuation of cardiac potassium currents in type 2 diabetic db/db mice. J Physiol. 2004;555:345-354. doi: 10.1113/jphysiol.2003.055590.
44. Lu Z, Jiang YP, Wu CY, Ballou LM, Liu S, Carpenter ES, Rosen MR, Cohen IS, Lin RZ. Increased persistent sodium current due to decreased PI3K signaling contributes to QT prolongation in the diabetic heart. Diabetes. 2013;62:4257-4265. doi: 10.2337/db13-0420.
45. Undrovinas AI, Maltsev VA, Kyle JW, Silverman N, Sabbah HN. Gating of the late Na+ channel in normal and failing human myocardium. J Mol Cell Cardiol. 2002;34:1477-1489.
46. Yang KC, Tseng YT, Nerbonne JM. Exercise training and PI3Kα- induced electrical remodeling is independent of cellular hypertrophy and Akt signaling. J Mol Cell Cardiol. 2012;53:532-541. doi: 10.1016/j. yjmcc.2012.07.004.
47. Kaur K, Zarzoso M, Ponce-Balbuena D, Guerrero-Serna G, Hou L, Musa H, Jalife J. TGF-β1, released by myofibroblasts, differentially regulates transcription and function of sodium and potassium channels in adult rat ventricular myocytes. PLoS One. 2013;8:e55391. doi: 10.1371/journal. pone.0055391.
48. Kobayashi T, Deak M, Morrice N, Cohen P. Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid induced protein kinase. Biochem J. 1999;344 Pt 1:189-197.
49. Park J, Leong ML, Buse P, Maiyar AC, Firestone GL, Hemmings BA. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J. 1999;18:3024-3033. doi: 10.1093/emboj/18.11.3024.
50. Kobayashi T, Cohen P. Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem J. 1999;339(Pt 2):319-328.
51. Loffing J, Flores SY, Staub O. Sgk kinases and their role in epithelial transport. Annu Rev Physiol. 2006;68:461-490. doi: 10.1146/annurev. physiol.68.040104.131654.
52. Abriel H, Loffing J, Rebhun JF, Pratt JH, Schild L, Horisberger JD, Rotin D, Staub O. Defective regulation of the epithelial Na+ channel by Nedd4 in Liddle's syndrome. J Clin Invest. 1999;103:667-673. doi: 10.1172/JCI5713.
53. Debonneville C, Flores SY, Kamynina E, Plant PJ, Tauxe C, Thomas MA, Münster C, Chraïbi A, Pratt JH, Horisberger JD, Pearce D, Loffing J, Staub O. Phosphorylation of Nedd4-2 by Sgk1 regulates epithelial Na(+) channel cell surface expression. EMBO J. 2001;20:7052-7059. doi: 10.1093/emboj/20.24.7052.
54. Abriel H, Kamynina E, Horisberger JD, Staub O. Regulation of the cardiac voltage-gated Na+ channel (H1) by the ubiquitin-protein ligase Nedd4. FEBS Lett. 2000;466:377-380.
55. Boehmer C, Wilhelm V, Palmada M, Wallisch S, Henke G, Brinkmeier H, Cohen P, Pieske B, Lang F. Serum and glucocorticoid inducible kinases in the regulation of the cardiac sodium channel SCN5A. Cardiovasc Res. 2003;57:1079-1084.
56. Das S, Aiba T, Rosenberg M, et al. Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling. Circulation. 2012;126:2208-2219. doi: 10.1161/CIRCULATIONAHA.112.115592.
57. Marionneau C, Lichti CF, Lindenbaum P, Charpentier F, Nerbonne JM, Townsend RR, Mérot J. Mass spectrometry-based identification of native cardiac Nav1.5 channel α subunit phosphorylation sites. J Proteome Res. 2012;11:5994-6007. doi: 10.1021/pr300702c.
58. Sun H, Oudit GY, Ramirez RJ, Costantini D, Backx PH. The phosphoinositide 3-kinase inhibitor LY294002 enhances cardiac myocyte contractility via a direct inhibition of Ik, slow currents. Cardiovasc Res. 2004;62:509-520. doi: 10.1016/j.cardiores.2004.01.029.
59. Wu J, Ding WG, Matsuura H, Tsuji K, Zang WJ, Horie M. Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel. Br J Pharmacol. 2009;156:377-387. doi: 10.1111/j.1476-5381.2008.00017.x.
60. Zhang Y, Wang H, Wang J, Han H, Nattel S, Wang Z. Normal function of HERG K+ channels expressed in HEK293 cells requires basal protein kinase B activity. FEBS Lett. 2003;534:125-132.
61. Maier G, Palmada M, Rajamanickam J, Shumilina E, Böhmer C, Lang F. Upregulation of HERG channels by the serum and glucocorticoid inducible kinase isoform SGK3. Cell Physiol Biochem. 2006;18:177-186. doi: 10.1159/000097666.
62. Lamothe SM, Zhang S. The serum- and glucocorticoid-inducible kinases SGK1 and SGK3 regulate hERG channel expression via ubiquitin ligase Nedd4-2 and GTPase Rab11. J Biol Chem. 2013;288:15075-15084. doi: 10.1074/jbc.M113.453670.
63. Pakladok T, Almilaji A, Munoz C, Alesutan I, Lang F. PIKfyve sensitivity of hERG channels. Cell Physiol Biochem. 2013;31:785-794. doi: 10.1159/000350096.
64. Gentile S, Darden T, Erxleben C, Romeo C, Russo A, Martin N, Rossie S, Armstrong DL. Rac GTPase signaling through the PP5 protein phosphatase. Proc Natl Acad Sci U S A. 2006;103:5202-5206. doi: 10.1073/pnas.0600080103.
65. Gentile S, Martin N, Scappini E, Williams J, Erxleben C, Armstrong DL. The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity. Proc Natl Acad Sci U S A. 2008;105:14704-14708. doi: 10.1073/pnas.0802250105.
66. Storey NM, Gentile S, Ullah H, Russo A, Muessel M, Erxleben C, Armstrong DL. Rapid signaling at the plasma membrane by a nuclear receptor for thyroid hormone. Proc Natl Acad Sci U S A. 2006;103:5197-5201. doi: 10.1073/pnas.0600089103.
67. Storey NM, O'Bryan JP, Armstrong DL. Rac and Rho mediate opposing hormonal regulation of the ether-a-go-go-related potassium channel. Curr Biol. 2002;12:27-33.
68. Bezzina CR, Verkerk AO, Busjahn A, Jeron A, Erdmann J, Koopmann TT, Bhuiyan ZA, Wilders R, Mannens MM, Tan HL, Luft FC, Schunkert H, Wilde AA. A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res. 2003;59:27-36.
69. Crotti L, Hu D, Barajas-Martinez H, De Ferrari GM, Oliva A, Insolia R, Pollevick GD, Dagradi F, Guerchicoff A, Greco F, Schwartz PJ, Viskin S, Antzelevitch C. Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant. Heart Rhythm. 2012;9:1104-1112. doi: 10.1016/j.hrthm.2012.02.014.
70. Busjahn A, Seebohm G, Maier G, Toliat MR, Nürnberg P, Aydin A, Luft FC, Lang F. Association of the serum and glucocorticoid regulated kinase (sgk1) gene with QT interval. Cell Physiol Biochem. 2004;14:135-142. doi: 10.1159/000078105.
71. Embark HM, Böhmer C, Vallon V, Luft F, Lang F. Regulation of KCNE1-dependent K(+) current by the serum and glucocorticoid-inducible kinase (SGK) isoforms. Pflugers Arch. 2003;445:601-606. doi: 10.1007/s00424-002-0982-y.
72. Andersen MN, Krzystanek K, Petersen F, Bomholtz SH, Olesen SP, Abriel H, Jespersen T, Rasmussen HB. A phosphoinositide 3-kinase (PI3K)- serum- and glucocorticoid-inducible kinase 1 (SGK1) pathway promotes Kv7.1 channel surface expression by inhibiting Nedd4-2 protein. J Biol Chem. 2013;288:36841-36854. doi: 10.1074/jbc.M113.525931.
73. Jespersen T, Membrez M, Nicolas CS, Pitard B, Staub O, Olesen SP, Baró I, Abriel H. The KCNQ1 potassium channel is down-regulated by ubiquitylating enzymes of the Nedd4/Nedd4-like family. Cardiovasc Res. 2007;74:64-74. doi: 10.1016/j.cardiores.2007.01.008.
74. Seebohm G, Strutz-Seebohm N, Birkin R, et al. Regulation of endocytic recycling of KCNQ1/KCNE1 potassium channels. Circ Res. 2007;100:686-692. doi: 10.1161/01.RES.0000260250.83824.8f.
75. Seebohm G, Strutz-Seebohm N, Ureche ON, et al. Long QT syndromeassociated mutations in KCNQ1 and KCNE1 subunits disrupt normal endosomal recycling of IKs channels. Circ Res. 2008;103:1451-1457. doi: 10.1161/CIRCRESAHA.108.177360.
76. Millis RM, Alvin ZV, Zhao A, Haddad GE. Effects of IGF-1 on I(K) and I(K1) Channels via PI3K/Akt Signaling in Neonatal Cardiac Myocytes. Int J Cell Biol. 2012;2012:712153. doi: 10.1155/2012/712153.
77. Teos LY, Zhao A, Alvin Z, Laurence GG, Li C, Haddad GE. Basal and IGF-I-dependent regulation of potassium channels by MAP kinases and PI3-kinase during eccentric cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2008;295:H1834-H1845. doi: 10.1152/ajpheart.321.2008.
78. Yang KC, Foeger NC, Marionneau C, Jay PY, McMullen JR, Nerbonne JM. Homeostatic regulation of electrical excitability in physiological cardiac hypertrophy. J Physiol. 2010;588:5015-5032. doi: 10.1113/jphysiol.2010.197418.
79. Zhang Y, Xiao J, Wang H, Luo X, Wang J, Villeneuve LR, Zhang H, Bai Y, Yang B, Wang Z. Restoring depressed HERG K+ channel function as a mechanism for insulin treatment of abnormal QT prolongation and associated arrhythmias in diabetic rabbits. Am J Physiol Heart Circ Physiol. 2006;291:H1446-H1455. doi: 10.1152/ajpheart.01356.2005.
80. Blair LA, Bence-Hanulec KK, Mehta S, Franke T, Kaplan D, Marshall J. Akt-dependent potentiation of L channels by insulin-like growth factor-1 is required for neuronal survival. J Neurosci. 1999;19:1940-1951.
81. Blair LA, Marshall J. IGF-1 modulates N and L calcium channels in a PI 3-kinase-dependent manner. Neuron. 1997;19:421-429.
82. Le Blanc C, Mironneau C, Barbot C, Henaff M, Bondeva T, Wetzker R, Macrez N. Regulation of vascular L-type Ca2+ channels by phosphatidylinositol 3,4,5-trisphosphate. Circ Res. 2004;95:300-307. doi: 10.1161/01.RES.0000138017.76125.8b.
83. Quignard JF, Mironneau J, Carricaburu V, Fournier B, Babich A, Nurnberg B, Mironneau C, Macrez N. Phosphoinositide 3-kinase gamma mediates angiotensin II-induced stimulation of L-type calcium channels in vascular myocytes. J Biol Chem. 2001;276:32545-32551. doi: 10.1074/jbc.M102582200.
84. Viard P, Exner T, Maier U, Mironneau J, Nürnberg B, Macrez N. Gbetagamma dimers stimulate vascular L-type Ca2+ channels via phosphoinositide 3-kinase. FASEB J. 1999;13:685-694.
85. Yano N, Tseng A, Zhao TC, Robbins J, Padbury JF, Tseng YT. Temporally controlled overexpression of cardiac-specific PI3Kalpha induces enhanced myocardial contractility-a new transgenic model. Am J Physiol Heart Circ Physiol. 2008;295:H1690-H1694. doi: 10.1152/ajpheart.00531.2008.
86. Kim YK, Kim SJ, Yatani A, et al. Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt. J Biol Chem. 2003;278:47622-47628. doi: 10.1074/jbc.M305909200.
87. Rota M, Boni A, Urbanek K, Padin-Iruegas ME, Kajstura TJ, Fiore G, Kubo H, Sonnenblick EH, Musso E, Houser SR, Leri A, Sussman MA, Anversa P. Nuclear targeting of Akt enhances ventricular function and myocyte contractility. Circ Res. 2005;97:1332-1341. doi: 10.1161/01.RES.0000196568.11624.ae.
88. Crackower MA, Oudit GY, Kozieradzki I, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 2002;110:737-749.
89. Lu Z, Jiang YP, Xu XH, Ballou LM, Cohen IS, Lin RZ. Decreased L-type Ca2+ current in cardiac myocytes of type 1 diabetic Akita mice due to reduced phosphatidylinositol 3-kinase signaling. Diabetes. 2007;56:2780-2789. doi: 10.2337/db06-1629.
90. Viard P, Butcher AJ, Halet G, Davies A, Nürnberg B, Heblich F, Dolphin AC. PI3K promotes voltage-dependent calcium channel trafficking to the plasma membrane. Nat Neurosci. 2004;7:939-946. doi: 10.1038/nn1300.
91. Catalucci D, Zhang DH, DeSantiago J, Aimond F, Barbara G, Chemin J, Bonci D, Picht E, Rusconi F, Dalton ND, Peterson KL, Richard S, Bers DM, Brown JH, Condorelli G. Akt regulates L-type Ca2+ channel activity by modulating Cavalpha1 protein stability. J Cell Biol. 2009;184:923-933. doi: 10.1083/jcb.200805063.
92. Alloatti G, Marcantoni A, Levi R, Gallo MP, Del Sorbo L, Patrucco E, Barberis L, Malan D, Azzolino O, Wymann M, Hirsch E, Montrucchio G. Phosphoinositide 3-kinase gamma controls autonomic regulation of the mouse heart through Gi-independent downregulation of cAMP level. FEBS Lett. 2005;579:133-140. doi: 10.1016/j.febslet.2004.11.059.
93. Marcantoni A, Levi RC, Gallo MP, Hirsch E, Alloatti G. Phosphoinositide 3-kinasegamma (PI3Kgamma) controls L-type calcium current (ICa,L) through its positive modulation of type-3 phosphodiesterase (PDE3). J Cell Physiol. 2006;206:329-336. doi: 10.1002/jcp.20467.
94. Kerfant BG, Zhao D, Lorenzen-Schmidt I, Wilson LS, Cai S, Chen SR, Maurice DH, Backx PH. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ Res. 2007;101:400-408. doi: 10.1161/CIRCRESAHA.107.156422.
95. Rose RA, Kabir MG, Backx PH. Altered heart rate and sinoatrial node function in mice lacking the cAMP regulator phosphoinositide 3-kinase-gamma. Circ Res. 2007;101:1274-1282. doi: 10.1161/CIRCRESAHA.107.158428.
96. Wang DW, Kiyosue T, Shigematsu S, Arita M. Abnormalities of K+ and Ca2+ currents in ventricular myocytes from rats with chronic diabetes. Am J Physiol. 1995;269:H1288-H1296.
97. Pereira L, Matthes J, Schuster I, Valdivia HH, Herzig S, Richard S, Gómez AM. Mechanisms of [Ca2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes. 2006;55:608-615.
98. Lu Z, Ballou LM, Jiang YP, Cohen IS, Lin RZ. Restoration of defective L-type Ca2+ current in cardiac myocytes of type 2 diabetic db/db mice by Akt and PKC-ι. J Cardiovasc Pharmacol. 2011;58:439-445. doi: 10.1097/FJC.0b013e318228e68c.